Business
SANUWAVE Health Presents dermaPACE System Treatment Study Results Showing Enhanced Localized Wound Tissue Oxygenation
SUWANEE, GA / ACCESSWIRE / May 27, 2021 / SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"SUWANEE, GA / ACCESSWIRE / May 27, 2021 / SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field today presented results from a clinical case series that demonstrated improved wound healing when treated with its FDA-cleared, non-invasive pulsed acoustic cellular expression system dermaPACE® System. The study: A Non-invasive Focused Extracorporeal Shockwave Therapy System Promotes Increased Tissue Oxygen Saturation in Chronic Wounds in Persons with Diabetes, was published in the American Journal of Nursing Science in May 2021.The study was conducted in a clinical practice setting and concentrated on 15 wounds from 14 patients with a chronic foot or ankle wound and a diagnosed history of diabetes wounds observed between January 2019 and December 2019. The wounds that were treated had an average age of more than 12 weeks. Each patient was run through a screening period and those that entered the study had failed to achieve at least a 50% wound area reduction in four weeks of treatment with standard care. The main objective of the study was to observe the effects of dermaPACE System's focused shockwaves on tissue oxygen saturation within the wound bed as measured using near-infrared spectroscopy. Secondary objectives were to monitor the wound response to the treatment.Scientists and researchers have been examining the effects of external physical force manipulation on tissue to improve wound healing. Focused Extracorporeal Shock Wave Therapy (F-ESWT) is a non-invasive treatment that can be safely and easily performed in the outpatient setting as an adjunctive therapy. SANUWAVE's dermaPACE system is an FDA-cleared F-ESWT.Treatment with the dermaPACE System over four weeks (one treatment per week) resulted in all patients demonstrating a statistically significant increase in tissue oxygen saturation within the wound bed, a key component of wound healing. Wound bed tissue oxygen saturation increased approximately 25% (P=0.0008). Additionally, the results showed all 15 wounds demonstrated a decrease in wound area and seven, or 46.7%, of the wounds experienced full wound closure (P=0.0007).The results of this case study are anot...